374 related articles for article (PubMed ID: 25544392)
1. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
Wendroth SM; Mentrikoski MJ; Wick MR
Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
[TBL] [Abstract][Full Text] [Related]
2. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
3. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
4. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
5. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
Hafez NH; Shaaban HM
Turk Patoloji Derg; 2018; 34(2):143-149. PubMed ID: 29235613
[TBL] [Abstract][Full Text] [Related]
6. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors.
Chia SY; Thike AA; Cheok PY; Tan PH
Breast; 2010 Oct; 19(5):355-9. PubMed ID: 20347310
[TBL] [Abstract][Full Text] [Related]
7. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology.
Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U
Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas.
Liu H; Shi J; Prichard JW; Gong Y; Lin F
Am J Clin Pathol; 2014 May; 141(5):648-55. PubMed ID: 24713735
[TBL] [Abstract][Full Text] [Related]
9. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups.
Ni YB; Tsang JY; Chan SK; Tse GM
Histopathology; 2015 Jul; 67(1):96-105. PubMed ID: 25425335
[TBL] [Abstract][Full Text] [Related]
10. Signet ring variant of lobular carcinoma of the breast: a clinicopathologic and immunohistochemical study.
Raju U; Ma CK; Shaw A
Mod Pathol; 1993 Sep; 6(5):516-20. PubMed ID: 8248106
[TBL] [Abstract][Full Text] [Related]
11. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens.
Yan Z; Gidley J; Horton D; Roberson J; Eltoum IE; Chhieng DC
Diagn Cytopathol; 2009 Jul; 37(7):475-8. PubMed ID: 19217055
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
Demir H; Turna H; Can G; Ilvan S
J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
[TBL] [Abstract][Full Text] [Related]
14. Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas.
Luo MH; Huang YH; Ni YB; Tsang JY; Chan SK; Shao MM; Tse GM
Hum Pathol; 2013 Jul; 44(7):1241-50. PubMed ID: 23332923
[TBL] [Abstract][Full Text] [Related]
15. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens.
Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z
Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast.
Honma N; Takubo K; Arai T; Younes M; Kasumi F; Akiyama F; Sakamoto G
APMIS; 2006 Oct; 114(10):712-9. PubMed ID: 17004974
[TBL] [Abstract][Full Text] [Related]
18. Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens.
Braxton DR; Cohen C; Siddiqui MT
Diagn Cytopathol; 2015 Apr; 43(4):271-7. PubMed ID: 25088841
[TBL] [Abstract][Full Text] [Related]
19. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity.
Bhargava R; Beriwal S; Dabbs DJ
Am J Clin Pathol; 2007 Jan; 127(1):103-13. PubMed ID: 17145637
[TBL] [Abstract][Full Text] [Related]
20. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer.
Fritzsche FR; Thomas A; Winzer KJ; Beyer B; Dankof A; Bellach J; Dahl E; Dietel M; Kristiansen G
Histol Histopathol; 2007 Nov; 22(11):1221-30. PubMed ID: 17647195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
